title: Mycoplasma genitalium presence, resistance and epidemiology in Greenland.
abstract: OBJECTIVE
  Greenland reports the highest rates of chlamydial infection and gonorrhea in the Arctic. Our objective was to determine the presence, and describe the basic epidemiology, of Mycoplasma genitalium for Greenland.
  
  
  METHODS
  Cross-sectional study.
  
  
  METHODS
  314 residents from Nuuk and Sisimiut, between the ages of 15 and 65 years, participated in "Inuulluataarneq" (the Greenland Sexual Health Project) between July 2008 and November 2009. Participants provided self-collected samples for sexually transmitted infection (STI) testing and completed a sexual health survey. Descriptive statistics and logistic regression were used to summarize the basic characteristics of STI cases overall and M. genitalium and Chlamydia trachomatis specifically. Clinically relevant characteristics in each full model were gender (male or female), age (in years), age at sexual debut (in years), number of sexual partners in the past 3 months (continuous) and history of forced sex and community.
  
  
  RESULTS
  The overall prevalence of STIs was 19.0%, specifically: 9.8% for M. genitalium and 9.4% for C. trachomatis; 100% of M. genitalium-positive cases carried macrolide resistance determinants. Being female [OR = 3.2; 95% confidence interval (CI): 1.1-9.8] and younger age (OR = 0.9; 95% CI: 0.9-1.0) were associated with M. genitalium positivity. Age was also associated with C. trachomatis (OR = 0.9; 95% CI: 0.8-0.9) and STI positivity overall (OR = 0.9; 95% CI: 0.9-0.9).
  
  
  CONCLUSIONS
  We observed a high prevalence of M. genitalium and macrolide resistance in this study. A better understanding of M. genitalium sequelae is needed to inform policy around testing, treatment, control and antibiotic use.
authors.affiliation: Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. dionne.gesink@utoronto.ca
authors.forename: Dionne C
authors.initials: DC
authors.lastname: Gesink
authors.forename: Gert
authors.initials: G
authors.lastname: Mulvad
authors.forename: Ruth
authors.initials: R
authors.lastname: Montgomery-Andersen
authors.forename: Upaluk
authors.initials: U
authors.lastname: Poppel
authors.forename: Stephan
authors.initials: S
authors.lastname: Montgomery-Andersen
authors.forename: Aka
authors.initials: A
authors.lastname: Binzer
authors.forename: Lee
authors.initials: L
authors.lastname: Vernich
authors.forename: Gillian
authors.initials: G
authors.lastname: Frosst
authors.forename: Flemming
authors.initials: F
authors.lastname: Stenz
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Rink
authors.forename: Ove Rosing
authors.initials: OR
authors.lastname: Olsen
authors.forename: Anders
authors.initials: A
authors.lastname: Koch
authors.forename: Jørgen Skov
authors.initials: JS
authors.lastname: Jensen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D017963:Azithromycin / Q000627:therapeutic use; D002690:Chlamydia Infections / Q000453:epidemiology*; D002692:Chlamydia trachomatis / Q000302:isolation & purification*; D003430:Cross-Sectional Studies; D024881:Drug Resistance, Bacterial; D004352:Drug Resistance, Microbial; D005260:Female; D006116:Greenland / Q000453:epidemiology; D006306:Health Surveys; D006801:Humans; D008297:Male; D008875:Middle Aged; D009175:Mycoplasma Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D045704:Mycoplasma genitalium / Q000302:isolation & purification*; D015995:Prevalence; D012749:Sexually Transmitted Diseases / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D055815:Young Adult
chemical_list: D017963:Azithromycin